Core Viewpoint - The company Baipusais announced an expected net profit attributable to shareholders of 160 million to 190 million yuan for 2025, indicating a year-on-year growth of 29.21% to 53.43% [1] - The projected operating revenue is expected to reach 837 million yuan, reflecting an approximate year-on-year increase of 30% [1] Financial Performance - Expected net profit for 2025: 160 million to 190 million yuan [1] - Year-on-year growth in net profit: 29.21% to 53.43% [1] - Projected operating revenue for 2025: 837 million yuan [1] - Year-on-year growth in operating revenue: approximately 30% [1]

Core Viewpoint - Baipusais (301080.SZ) has disclosed its performance forecast for the year 2025, expecting a net profit attributable to shareholders of between 160 million yuan and 190 million yuan, representing a year-on-year growth of 29.21% to 53.43% [1] Summary by Category - **Net Profit Forecast** - The company anticipates a net profit of 160 million to 190 million yuan for 2025, indicating a significant increase compared to the previous year [1] - **Adjusted Net Profit** - The forecasted net profit, excluding non-recurring gains and losses, is expected to be between 155 million and 185 million yuan, reflecting a year-on-year growth of 30.13% to 55.31% [1]

Core Viewpoint - The company Baipusais (301080.SZ) has disclosed its performance forecast for the year 2025, indicating a significant increase in net profit attributed to shareholders [1] Financial Performance - The company expects a net profit attributable to shareholders ranging from 160 million to 190 million yuan, representing a year-on-year growth of 29.21% to 53.43% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 155 million and 185 million yuan, with a year-on-year increase of 30.13% to 55.31% [1]

证券代码：301080 证券简称：百普赛斯 公告编号：2026-004 北京百普赛斯生物科技股份有限公司 关于与专业投资机构共同投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资概述 北京百普赛斯生物科技股份有限公司（以下简称"公司"）全资子公司 ACROBIOSYSTEMS HONGKONG LIMITED 之全资子公司 ACROBiosystems Corp.以自 有资金出资不超过 100 万美元认购专业投资机构 BroadOak Asset Management, LLC 正在募集的基金的份额（0.9%），成为其有限合伙人。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第2号——创业板上市公司规范运作》等相关法律法规以及《公司章 程》的规定，本次投资属于管理层审批权限内，无需提交董事会审议。 主要投资领域：生命科学工具及医药服务领域企业，重点关注生命科学工具、 诊断服务、研究及生物医药外包服务等细分领域 关联关系或其他利益关系说明：BroadOak Asset Management, LLC与公司不 ...

Financial Projections - The company expects a net profit attributable to shareholders of between ¥160 million and ¥190 million for 2025, representing a year-on-year growth of 29.21% to 53.43%[4] - The net profit after deducting non-recurring gains and losses is projected to be between ¥155 million and ¥185 million, reflecting a year-on-year increase of 30.13% to 55.31%[4] - The company anticipates a revenue of ¥837 million for 2025, which indicates a year-on-year growth of approximately 30%[6] - The specific data for the 2025 performance will be detailed in the annual report, and investors are advised to make cautious decisions[10] Product and Service Development - The product matrix includes over 5,000 SKUs, focusing on a comprehensive ecosystem of "products + services + platforms" to meet the full lifecycle needs of global clients[7] - The company is focusing on innovative therapy research, particularly in areas such as in vivo CAR-T/CAR-NK, XDC/ADC, and cell and gene therapy[8] - The company has developed several key products, including AI-engineered recombinant proteins and GMP-grade growth factors for stem cell drug development[8] Supply Chain and Quality Management - The company has established a global supply chain network covering nearly 80 countries and regions, serving over 11,000 end customers, including major pharmaceutical companies[7] - Cost control and quality stability have been enhanced through optimized protein expression efficiency and improved global supply chain management[9] - The company adheres to international quality standards such as ISO9001:2015 and cGMP to enhance operational efficiency and global delivery capabilities[9]

Market Overview - The market experienced fluctuations throughout the day, with the Shanghai Composite Index rising by 0.27%, the Shenzhen Component Index increasing by 0.09%, and the ChiNext Index declining by 0.57% [1] - A total of 1,739 stocks rose, with 84 hitting the daily limit up, while 3,640 stocks fell [2] Stock Performance - Among the rising stocks, 169 had gains exceeding 7%, 105 gained between 5-7%, and 252 rose between 3-5% [3] - Conversely, 2,912 stocks saw declines of 0-3%, 558 fell by 3-5%, and 58 dropped by more than 7% [3] - Resource stocks surged, particularly gold stocks, with Sichuan Gold achieving four consecutive limit-ups, and both Zhaojin Mining and Hunan Gold achieving three consecutive limit-ups [3] Sector Highlights - Oil and gas stocks collectively rose, with Tongyuan Petroleum and Zhongman Petroleum hitting the daily limit up, and China National Offshore Oil Corporation (CNOOC) increasing over 6% to reach a new high [4] - The non-ferrous metals sector strengthened, with silver stocks achieving seven consecutive limit-ups, and China Aluminum hitting the daily limit up, marking a 16-year high [5] - The coal sector also saw gains, with Shanxi Coking Coal and Shaanxi Black Cat both hitting the daily limit up [7] Declines - The pharmaceutical and medical stocks faced adjustments, with Bibet and Baipusai dropping over 10% [8] Trading Volume and Activity - The total trading volume reached approximately 29,922.93 billion, with a notable increase in trading activity for major ETFs, including the CSI 300 ETF from Huatai-PB, which exceeded 30 billion in trading volume [11]

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

Market Overview - The market experienced fluctuations on January 28, with the Shanghai Composite Index rising by 0.27%, the Shenzhen Component Index increasing by 0.09%, and the ChiNext Index declining by 0.57% [2][12]. - A total of 1,739 stocks rose, 84 stocks hit the daily limit up, while 3,640 stocks fell [3][13]. Sector Performance - Resource stocks surged, with gold stocks leading the gains. Sichuan Gold achieved a four-day limit up, while Zhaojin Mining and Hunan Gold saw three consecutive limit ups [4][14]. - Oil and gas stocks collectively rose, with Tongyuan Petroleum and Zhongman Petroleum hitting the limit up, and China National Offshore Oil Corporation (CNOOC) increasing over 6% to reach a new high [5][16]. - The non-ferrous metals sector strengthened, with Silver Industry (Wei Quan) achieving seven consecutive limit ups, and China Aluminum hitting the limit up, marking a 16-year high [6][17]. - The coal sector also saw gains, with Shanxi Coking Coal and Shaanxi Black Cat hitting the limit up [7][18]. Declines - The pharmaceutical and medical stocks faced adjustments, with Bibete and Baipusais falling over 10% [8][19]. Trading Activity - Significant trading activity was noted, with the HuShen 300 ETF from Huatai-PB exceeding 30 billion yuan in trading volume, and other ETFs like the HuShen 300 ETF from E Fund and the CSI 500 ETF also surpassing 20 billion yuan [9][20]. - A report from CITIC Securities indicated that in previous bull markets, overheating trading conditions prompted cooling policies to prevent severe consequences, suggesting that the current proactive cooling measures are aimed at regulating market momentum without altering the overall positive policy stance [9][20].

Market Overview - The three major indices showed mixed performance, with the Shanghai Composite Index rising by 0.49% to 4160.01, the Shenzhen Component Index increasing by 0.09% to 14342.74, and the ChiNext Index declining by 0.37% to 3330.39 [1][2]. Sector Performance - Precious metals, industrial metals, and petrochemicals sectors performed strongly, while solar energy, pharmaceuticals, and aerospace sectors experienced fluctuations [2]. - The basic metals sector saw significant gains, with copper and aluminum industries leading the rise, as multiple stocks hit the daily limit up [6]. Stock Highlights - Notable stocks included China National Offshore Oil Corporation, China Petroleum, and China Unicom, which showed strong performance [4]. - The aluminum futures market saw a rise of over 4%, with the main contract reported at 25345 yuan/ton [8]. Biotechnology Sector - The biotechnology sector faced declines, with several companies such as Zhijiang Biology and Baipusais losing over 9% [10][11]. Solar Energy Sector - The solar energy sector faced downward adjustments, with companies like High Measurement and Maiwei experiencing drops exceeding 6% [11].

重组蛋白板块领跌，下跌1.42%，其中百普赛斯下跌7.3%，近岸蛋白下跌2.81%，海特生物下跌2.16%， 三生国健跌超3%。（AI生成） ...